Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canbridge PharmaceuticalsHKSE:01228 +2.50%48 Quick Ratio is 0.20 as of Dec. 2025, which is 76% below its 10-year median of 0.83. GuruFocus rates HKSE:01228 with a GF Score™ of 48/100 and a GF Value™ of HK$0.38 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Canbridge Pharmaceuticals ranks worse than 94.54% on this metric.
Canbridge Pharmaceuticals has a quick ratio of 0.20. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Canbridge Pharmaceuticals's Quick Ratio or its related term are showing as below:
HKSE:01228'
s Quick Ratio Range Over the Past 10 Years
Min: 0.08 Med: 0.83 Max: 4.3
Current: 0.2
During the past 7 years, Canbridge Pharmaceuticals's highest Quick Ratio was 4.30. The lowest was 0.08. And the median was 0.83.
HKSE:01228's Quick Ratio is ranked worse than 94.54% of 1410
companies
in the Biotechnology industry
Industry Median: 3.59
vs HKSE:01228: 0.20
Canbridge Pharmaceuticals (HKSE:01228) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Canbridge Pharmaceuticals Quick Ratio Related Terms
Canbridge Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01228 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Canbridge Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Canbridge Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (HKSE:01228) has a Quick Ratio of 0.20 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Canbridge Pharmaceuticals and its competitors. This is 76% below median its historical median of 0.83. Over the past decade, Canbridge Pharmaceuticals' Quick Ratio has ranged from 0.08 to 4.30. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #1333 out of 1410 companies in the Biotechnology industry, placing it in the top 94.5%.
Is Canbridge Pharmaceuticals' Quick Ratio too high?
Canbridge Pharmaceuticals' current Quick Ratio of 0.20 is 76% below median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 4.30. The Biotechnology industry median Quick Ratio is 3.59. Canbridge Pharmaceuticals' value of 0.20 is 94.4% below this industry median. Based on the distribution chart, Canbridge Pharmaceuticals ranks #1333 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #1333 out of 1410 companies for Quick Ratio. This places Canbridge Pharmaceuticals in the lower half of its industry. The industry median Quick Ratio is 3.59. Canbridge Pharmaceuticals' value of 0.20 is 94.4% below this benchmark. Historically, Canbridge Pharmaceuticals' own Quick Ratio has ranged from 0.08 to 4.30 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 3.59, Canbridge Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canbridge Pharmaceuticals's current Quick Ratio of 0.20 is 94.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Canbridge Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canbridge Pharmaceuticals's current Quick Ratio is 0.20, which is 76% below median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.38, compared to a current price of HK$2.05 — trading 439.5% above its estimated fair value. The current Quick Ratio is 0.20, which is 76% below median its 10-year median of 0.83 and 94.4% below the Biotechnology industry median of 3.59. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current Quick Ratio is 0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of HK$2.05 is trading 439.5% above its estimated GF Value™ of HK$0.38.
GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for HKSE:01228:
Quick Ratio: 0.20 (76% below median its 10-year median of 0.83)
GF Value™: HK$0.38 vs. price of HK$2.05 (439.5% above fair value)
Industry Position: 94.4% below the Biotechnology median (#1333 of 1410)
No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for HKSE:01228
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01228 has been successfully added to your 
